All In Biotech

Drug Trial Radar · NCT02124512

Blood Lipopolysaccharide (LPS) Rifaximin Study

Dietary Fat, Lipoprotein and Lipopolysaccharide: Role in Insulin Resistance

Last checked: Nov 20, 2026Latest source record: Aug 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Mar 2015

Primary completion

May 31, 2019

Study completion May 31, 2019

Sponsor

Lead sponsor
Philip KernAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Apr 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 35 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Metabolic syndrome is a condition involving elevated levels of fat in the blood, a tendency towards diabetes, hypertension, and too much fat around the abdomen (an increased waistline). Individuals with metabolic syndrome often have impaired glucose tolerance, which is a condition where blood sugar is normal when fasting (before eating), but is too high after drinking a sugary drink. This is due to an abnormality in the body's sensitivity to insulin (insulin resistance), which is due in part to an inability of the muscle to take up glucose. People with metabolic syndrome have inflammation in their fat tissue and in their blood stream, and the changes in the level of inflammatory chemicals produced by cells in your fat tissues will be studied. One possible source of the inflammation may be the bacteria in the intestine. When individuals eat fatty foods, some of the bacterial products become attached to the fat in their blood and then get directed to fat tissue. The investigators wish to determine whether individuals have an excessive amount of inflammation in their fat tissues, and whether this inflammation comes from the bacteria in their intestines. To determine this, the investigators wish to treat individuals with an antibiotic that reduces the bacteria in their intestines and in their blood, and determine whether this reduces their overall level of inflammation.

Conditions

  • Obese
  • Insulin Resistance
  • Metabolic Syndrome

Interventions

  • Rifaximin SSDDrug

    Study Drug dosing will be 80 mg SSD once daily

  • PlaceboOther

    80 mg placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Circulating LPSTime frame: 0, 4 and 8 hours at Baseline, and 0, 4 and 8 hours after 12 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Kentucky Center for Clinical and Translational Science

    Lexington, Kentucky

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.